Detalhe da pesquisa
1.
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Clin Cancer Res
; 27(17): 4923-4936, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34145028
2.
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Clin Cancer Res
; 26(20): 5338-5347, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32694156